Santhosh RK

Indian science, decoded. Biotech · pharma · policy.

[Santhosh RK @Newscienceindia]

India makes ~20% of the world's generics, yet discovers a fraction of 1% of new molecules. China licenses molecules to global pharma for $130B+ a year. The future belongs to whoever owns the molecule, not the factory. #NewScienceIndia @DBTIndia @IndiaDST

[Santhosh RK @Newscienceindia]

@DBTIndia @cellogenindia @BIRAC_2012 A cell engager is a matchmaker: it grabs the cancer cell with one arm and the patient's own T cells with the other, so the immune system finds and kills the tumor. As mRNA, the body makes the drug itself — faster and cheaper. Big step for lymphoma patients.

[Santhosh RK @Newscienceindia]

New customs rulebook for pharma and device imports: officers must verify a CDSCO checklist — QR codes on APIs, 60%+ shelf life, valid licences — before releasing consignments. Traceability is the gate at the border. @CDSCO_INDIA_INF #NewScienceIndia #Pharma #MedDevices

[Santhosh RK @Newscienceindia]

@isro Simple version: El Niño warms the Pacific, slows upwelling of cold nutrient-rich water, and starves the tiny phytoplankton that feed ocean life. From space, EOS-06 watches the ocean lose its green. India cares because El Niño years often bring weaker monsoons.

[Santhosh RK @Newscienceindia]

Innovation is incomplete without investment. DBT and BIRAC launched BIO-NIVESH, putting 20 biotech startups in front of 50 investors in Delhi. Bioeconomy: $10B to $195B+ in a decade. Capital is the last missing piece. @DBTIndia @BIRAC_2012 #NewScienceIndia #Biotech

[Santhosh RK @Newscienceindia]

@isro Cryogenic engines burn super-cold hydrogen and oxygen, the most efficient propellants. This hot test clears CE20 for LVM3's C32 upper stage — the part that decides how much the rocket can carry to orbit. Every heavy mission, Gaganyaan included, rides on it.

[Santhosh RK @Newscienceindia]

CDSCO is moving from 'prior approval' to 'prior intimation' for manufacturing for testing and analysis — fewer approvals, more trust in the process. Risk-based regulation speeds science without softening safety. @CDSCO_INDIA_INF #NewScienceIndia #Pharma

[Santhosh RK @Newscienceindia]

Every biotech power learned one lesson: labs don't scale, capital does. BIO-NIVESH puts 20 biotech and deep-tech startups in a room with 50 investors — aiming India's $195B bioeconomy at $300B by 2030. @DBTIndia @BIRAC_2012 #NewScienceIndia #Biotech

[DBT-BIRAC @BIRAC_2012]

Bridging Innovation & Investment through BIO-NIVESH

BIRAC is pioneering a structured platform for sustained engagement between biotech startups, investors and industry.

Moving beyond conventional pitching, BIO-NIVESH will foster two-way dialogue, investment readiness, strategic partnerships and pathways to scale and commercialisation.

#BioNivesh #BIRAC #Biotechnology #BioInnovation #Startups #Investors #Innovation #ScaleUp #BiotechStartups #Investment #DeepTech #StartupEcosystem #GovernmentOfIndia

[Santhosh RK @Newscienceindia]

India is quietly cutting red tape for medical devices: outsourced sterilisation no longer needs a separate loan licence, and EU-approved devices without a local predicate can now skip fresh clinical investigations here. @CDSCO_INDIA_INF #NewScienceIndia #MedDevices

[Santhosh RK @Newscienceindia]

@RGambhir @isro Well said. ISRO as the early customer is the real story here — it gives the terminal flight heritage, and flight heritage is what turns a good lab result into a credible global supplier.

[Santhosh RK @Newscienceindia]

India is building laser links for space. Astrogate Labs unveiled the first indigenous optical inter-satellite terminal: 10 Gbps between satellites, ISRO as customer. Lab question to flight-ready product — this is how tech nations rise. @isro #NewScienceIndia #SpaceTech

[Santhosh RK @Newscienceindia]

A US patent just landed with an Indian space startup. GalaxEye syncs optical and radar sensors so satellites see through cloud cover and darkness — weather-agnostic imaging for global markets. Deep tech, built in India. @isro #NewScienceIndia #SpaceTech

[Santhosh RK @Newscienceindia]

ISRO and DBT are taking biology to orbit: space biotech experiments, a dedicated biotech rack for the Bharatiya Antariksh Station, and biomanufacturing for long-duration missions. Space biology is now national policy. #NewScienceIndia @isro @DBTIndia

[Santhosh RK @Newscienceindia]

₹5,000 crore for pharma and MedTech R&D — PRIP's second call opens mid-September. Up to ₹5 crore early-stage, ₹100 crore late-stage. Money is real; winners will be labs that spend it like innovators. @NITIAayog #NewScienceIndia #MedTech

[Santhosh RK @Newscienceindia]

https://t.co/gYhMN34tv1. If women were moved out of sight for this visit, ask: why should respecting one person make another invisible?

A personal vow should guide the person who takes it—not restrict someone who never took it.

Being a good host does not mean saying yes to everything. Pleasing the powerful should never matter more than treating people fairly.

One delegation is not Hinduism. One incident is not India.

Loving our faith and country means questioning unfair actions—not defending everything done in their name.

[Santhosh RK @Newscienceindia]

@elonmusk @Tesla As a Tesla owner, I’d opt-in in a heartbeat. Turn idle parking lot time into something meaningful.

[Santhosh RK @Newscienceindia]

@elonmusk @Tesla Real talk — the tech pieces (cameras + Dojo + FSD vision) already exist. The leap is mostly regulatory + privacy frameworks. Still, the idea of a decentralized safety net feels like the future.

[Santhosh RK @Newscienceindia]

@elonmusk @Tesla Just a thought… if Tesla actually builds ‘Finder’ and starts catching bad guys left and right, I’ll happily accept my royalty check for the name + concept. 😏 Standard inventor rate, of course.

[Santhosh RK @Newscienceindia]

Dear sir @narendramodi @PMOIndia Kindly request our office to look into this.
India runs the world's 3rd-largest clinical trial base.

China spends 4× more on R&D — and now licenses molecules to global pharma for $130B+ a year.

[Santhosh RK @Newscienceindia]

@SawyerMerritt https://t.co/93B90ZiNtN